TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Puma Biotechnology ( (PBYI) ) has shared an announcement.
On May 8, 2025, Puma Biotechnology, Inc. terminated Jeff J. Ludwig as its Chief Commercial Officer. The company will not appoint a new CCO and plans to distribute his responsibilities among existing sales and marketing staff.
Spark’s Take on PBYI Stock
According to Spark, TipRanks’ AI Analyst, PBYI is a Neutral.
Puma Biotechnology’s overall stock score reflects its financial improvements, technical momentum, and attractive valuation. However, the company’s challenges with revenue consistency and leverage, combined with mixed earnings call insights, temper the outlook. Long-term prospects may depend on successful execution of strategic initiatives and stabilization of revenue.
To see Spark’s full report on PBYI stock, click here.
More about Puma Biotechnology
Average Trading Volume: 371,917
Technical Sentiment Signal: Sell
Current Market Cap: $148.4M
For detailed information about PBYI stock, go to TipRanks’ Stock Analysis page.